Mylan N.V.

NAS: MYL

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 29, 2020, 7:45 p.m.

MYL
/zigman2/quotes/209413137/composite

$

17.08

Change

+0.01 +0.06%

Volume

Volume 831,753

Quotes are delayed by 20 min

/zigman2/quotes/209413137/composite

Previous close

$ 17.25

$ 17.07

Change

-0.18 -1.04%

Day low

Day high

$16.62

$17.37

Open

52 week low

52 week high

$12.75

$23.11

Open

Company Description

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The...

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Valuation

P/E Current

524.75

P/E Ratio (with extraordinary items)

140.98

P/E Ratio (without extraordinary items)

618.46

Price to Sales Ratio

0.90

Price to Book Ratio

0.87

Price to Cash Flow Ratio

5.76

Enterprise Value to EBITDA

7.59

Enterprise Value to Sales

1.84

Total Debt to Enterprise Value

0.57

Efficiency

Revenue/Employee

328,606.00

Income Per Employee

480.00

Receivables Turnover

3.87

Total Asset Turnover

0.36

Liquidity

Current Ratio

1.21

Quick Ratio

0.73

Cash Ratio

0.11

Profitability

Gross Margin

36.40

Operating Margin

8.55

Pretax Margin

1.34

Net Margin

0.15

Return on Assets

0.05

Return on Equity

0.14

Return on Total Capital

3.87

Return on Invested Capital

0.07

Capital Structure

Total Debt to Total Equity

108.76

Total Debt to Total Capital

52.10

Total Debt to Total Assets

41.35

Long-Term Debt to Equity

95.84

Long-Term Debt to Total Capital

45.91

Officers and Executives

Name Age Officer Since Title
Mr. Robert J. Coury 58 2012 Executive Chairman
Ms. Heather M. Bresch 49 2007 Chief Operating & Integration Officer
Mr. Rajiv Malik 58 2007 President & Executive Director
Mr. Kenneth Scott Parks 55 2016 Chief Financial Officer
Ms. Andrea B. Miller - - Head-Global Research & Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/03/2020 Heather M. Bresch
Chief Executive Officer; Director
22,357   Derivative/Non-derivative trans. at $16.29 per share. 364,195
03/03/2020 Heather M. Bresch
Chief Executive Officer; Director
8,942   Derivative/Non-derivative trans. at $16.29 per share. 145,665
03/03/2020 Rajiv Malik
President; Director
13,677   Derivative/Non-derivative trans. at $16.29 per share. 222,798
03/03/2020 Rajiv Malik
President; Director
5,471   Derivative/Non-derivative trans. at $16.29 per share. 89,122
03/03/2020 Anthony Mauro
Chief Commercial Officer
6,016   Derivative/Non-derivative trans. at $16.29 per share. 98,000
03/03/2020 Anthony Mauro
Chief Commercial Officer
2,406   Derivative/Non-derivative trans. at $16.29 per share. 39,193
03/03/2020 Kenneth Scott Parks
Chief Financial Officer
4,361   Derivative/Non-derivative trans. at $16.29 per share. 71,040
03/03/2020 Kenneth Scott Parks
Chief Financial Officer
1,745   Derivative/Non-derivative trans. at $16.29 per share. 28,426
03/03/2020 Paul B. Campbell
See Remarks
902   Derivative/Non-derivative trans. at $16.29 per share. 14,693
03/03/2020 Paul B. Campbell
See Remarks
75   Derivative/Non-derivative trans. at $16.29 per share. 1,221
03/03/2020 Paul B. Campbell
See Remarks
364   Derivative/Non-derivative trans. at $16.29 per share. 5,929
03/03/2020 Heather M. Bresch
Chief Executive Officer; Director
50,355   Derivative/Non-derivative trans. at $0 per share. 0
03/03/2020 Heather M. Bresch
Chief Executive Officer; Director
20,141   Derivative/Non-derivative trans. at $0 per share. 0
03/03/2020 Rajiv Malik
President; Director
30,988   Derivative/Non-derivative trans. at $0 per share. 0
03/03/2020 Rajiv Malik
President; Director
12,395   Derivative/Non-derivative trans. at $0 per share. 0
03/03/2020 Anthony Mauro
Chief Commercial Officer
13,834   Derivative/Non-derivative trans. at $0 per share. 0
03/03/2020 Anthony Mauro
Chief Commercial Officer
5,533   Derivative/Non-derivative trans. at $0 per share. 0
03/03/2020 Kenneth Scott Parks
Chief Financial Officer
9,961   Derivative/Non-derivative trans. at $0 per share. 0
03/03/2020 Kenneth Scott Parks
Chief Financial Officer
3,984   Derivative/Non-derivative trans. at $0 per share. 0
03/03/2020 Paul B. Campbell
See Remarks
2,076   Derivative/Non-derivative trans. at $0 per share. 0
03/03/2020 Paul B. Campbell
See Remarks
220   Derivative/Non-derivative trans. at $0 per share. 0
03/03/2020 Paul B. Campbell
See Remarks
830   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Heather M. Bresch
Chief Executive Officer; Director
22,644   Derivative/Non-derivative trans. at $17.48 per share. 395,817
03/02/2020 Heather M. Bresch
Chief Executive Officer; Director
9,862   Derivative/Non-derivative trans. at $17.48 per share. 172,387
03/02/2020 Rajiv Malik
President; Director
14,793   Derivative/Non-derivative trans. at $17.48 per share. 258,581
03/02/2020 Rajiv Malik
President; Director
6,464   Derivative/Non-derivative trans. at $17.48 per share. 112,990
03/02/2020 Anthony Mauro
Chief Commercial Officer
6,759   Derivative/Non-derivative trans. at $17.48 per share. 118,147
03/02/2020 Anthony Mauro
Chief Commercial Officer
2,657   Derivative/Non-derivative trans. at $17.48 per share. 46,444
03/02/2020 Neil F. Dimick
Director
1,754   Derivative/Non-derivative trans. at $17.48 per share. 30,659
03/02/2020 Randall L. Vanderveen
Director
2,430   Derivative/Non-derivative trans. at $17.48 per share. 42,476
03/02/2020 Kenneth Scott Parks
Chief Financial Officer
6,806   Derivative/Non-derivative trans. at $17.48 per share. 118,968
03/02/2020 Kenneth Scott Parks
Chief Financial Officer
2,672   Derivative/Non-derivative trans. at $17.48 per share. 46,706
03/02/2020 Paul B. Campbell
See Remarks
131   Derivative/Non-derivative trans. at $17.48 per share. 2,289
03/02/2020 Paul B. Campbell
See Remarks
1,854   Derivative/Non-derivative trans. at $17.48 per share. 32,407
03/02/2020 Paul B. Campbell
See Remarks
57   Derivative/Non-derivative trans. at $17.48 per share. 996
03/02/2020 Paul B. Campbell
See Remarks
972   Derivative/Non-derivative trans. at $17.48 per share. 16,990
03/02/2020 Harry A. Korman
Director
2,430   Derivative/Non-derivative trans. at $17.48 per share. 42,476
03/02/2020 Robert J. Cindrich
Director
1,754   Derivative/Non-derivative trans. at $17.48 per share. 30,659
03/02/2020 JoEllen Lyons Dillon
Director
2,430   Derivative/Non-derivative trans. at $17.48 per share. 42,476
03/02/2020 Richard A. Mark
Director
3,779   Derivative/Non-derivative trans. at $17.48 per share. 66,056
03/02/2020 Pauline F. M. van der Meer Mohr
Director
2,430   Derivative/Non-derivative trans. at $17.48 per share. 42,476
03/02/2020 Heather M. Bresch
Chief Executive Officer; Director
51,002   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Heather M. Bresch
Chief Executive Officer; Director
22,211   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Rajiv Malik
President; Director
33,516   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Rajiv Malik
President; Director
14,645   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Anthony Mauro
Chief Commercial Officer
15,544   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Anthony Mauro
Chief Commercial Officer
6,102   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Melina E. Higgins
Director
6,011   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Neil F. Dimick
Director
6,011   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Sjoerd Steven Vollebregt
Director
6,011   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Randall L. Vanderveen
Director
6,011   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Mark W. Parrish
Director
6,011   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Kenneth Scott Parks
Chief Financial Officer
15,544   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Kenneth Scott Parks
Chief Financial Officer
6,102   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Paul B. Campbell
See Remarks
384   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Paul B. Campbell
See Remarks
4,129   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Paul B. Campbell
See Remarks
167   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Paul B. Campbell
See Remarks
1,980   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Harry A. Korman
Director
6,011   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Robert J. Cindrich
Director
6,011   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 JoEllen Lyons Dillon
Director
6,011   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Richard A. Mark
Director
9,007   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2020 Pauline F. M. van der Meer Mohr
Director
6,011   Derivative/Non-derivative trans. at $0 per share. 0
02/05/2020 Paul B. Campbell
See Remarks
11,611   Disposition at $23 per share. 267,053
02/05/2020 Paul B. Campbell
See Remarks
11,611   245,340
08/15/2019 Melina E. Higgins
Director
20,000   Acquisition at $17.68 per share. 353,600
08/14/2019 Sjoerd Steven Vollebregt
Director
11,000   Acquisition at $18.29 per share. 201,190
08/14/2019 Sjoerd Steven Vollebregt
Director
13,000   Acquisition at $19.25 per share. 250,250
08/13/2019 Sjoerd Steven Vollebregt
Director
10,000   Acquisition at $19.11 per share. 191,100
08/02/2019 Robert J. Coury
Director
49,859   Acquisition at $20.06 per share. 1,000,171
08/01/2019 Paul B. Campbell
See Remarks
752   Gift at $0 per share. 0
08/01/2019 Paul B. Campbell
See Remarks
752   11,129
08/01/2019 Paul B. Campbell
See Remarks
752   Gift at $0 per share. 0
07/31/2019 Richard A. Mark
Director
4,000   Acquisition at $20.97 per share. 83,880
06/24/2019 Robert J. Coury
Director
412,500   7,408,500
06/24/2019 Robert J. Coury
Director
750,000   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/myl

MarketWatch News on MYL

  1. The Stock Market’s Great Week Is Reason to Worry

    7:38 p.m. May 22, 2020

    - Ben Levisohn

  2. Mylan's stock gains 2%; guidance for 2020 reaffirmed

    8:50 a.m. May 11, 2020

    - Jaimy Lee

  3. Mylan's stock falls 2.8% premarket after Q1 results

    8:21 a.m. May 11, 2020

    - Tomi Kilgore

  4. Mylan affirms 2020 revenue outlook $11.5 bnl-$12.5 bln

    8:20 a.m. May 11, 2020

    - Tomi Kilgore

  5. Mylan Q1 revenue $2.62 bln vs. $2.50 bln a year ago; FactSet consensus $2.65 bln

    8:19 a.m. May 11, 2020

    - Tomi Kilgore

  6. Mylan Q1 EPS 4 cents vs. per-share loss 5 cents a year ago

    8:18 a.m. May 11, 2020

    - Tomi Kilgore

  7. Pfizer and Mylan Postpone Upjohn Deal. Analysts Aren’t Worried.

    9:10 a.m. March 27, 2020

    - Josh Nathan-Kazis

  8. Mylan Says India’s Lockdown Won’t Affect Drug Production

    2:24 p.m. March 25, 2020

    - Josh Nathan-Kazis

  9. Demand Spikes for a Drug Studied as Covid-19 Cure

    9:57 a.m. March 24, 2020

    - Josh Nathan-Kazis

  10. Loading more headlines...
/news/nonmarketwatch/company/us/myl

Other News on MYL

  1. Pfizer: A Post Spinoff Dividend Growth Opportunity

    3:14 p.m. May 21, 2020

    - Seeking Alpha

  2. J.P. Morgan picks spec pharma favorites after earnings

    4:07 p.m. May 19, 2020

    - Seeking Alpha

  3. 10-Q: UPJOHN INC

    4:50 p.m. May 12, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  4. Gilead inks deal to sell remdesivir in 127 countries

    2:14 p.m. May 12, 2020

    - Seeking Alpha

  5. 10-Q: MYLAN N.V.

    5:03 p.m. May 11, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  6. Mylan Earnings: 5 Things for MYL Stock Investors to Know About Q1

    2:25 p.m. May 11, 2020

    - InvestorPlace.com

  7. Mylan N.V. 2020 Q1 - Results - Earnings Call Presentation

    10:37 a.m. May 11, 2020

    - Seeking Alpha

  8. Mylan Q1 2020 Earnings Preview

    2:42 p.m. May 10, 2020

    - Seeking Alpha

  9. Spotlight On Tech Momo, Bitcoin Halving And 13Fs

    8:58 a.m. May 9, 2020

    - Seeking Alpha

  10. Agile Therapeutics: Billion Dollar Buy-Out Is On The Horizon

    8:45 a.m. May 1, 2020

    - Seeking Alpha

  11. Eagle Pharma and Teva prevail in Bendeka patent challenge

    9:08 a.m. April 28, 2020

    - Seeking Alpha

  12. Pfizer Quarterly Sales Fall

    7:41 a.m. April 28, 2020

    - Dave Sebastian

  13. Loading more headlines...

At a Glance

Mylan NV

Trident Place

Mosquito Way

Building 4

Hatfield, Hertfordshire AL10 9UL

Phone

44 1707853000

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$11.50B

Net Income

$16.80M

2019 Sales Growth

0.6%

Employees

35,000

/news/pressrelease/company/us/myl

Press Releases on MYL

  1. Coronavirus Impact on Generic Drugs Market

    7:52 a.m. May 25, 2020

    - Heraldkeepers

  2. Diuretics Market New Investments Expected to boost the Demand by 2025

    7:25 a.m. May 25, 2020

    - HTF Market Intelligence

  3. Rivastigmine Oral Market Enhancements and Demand Analysis 2020 to 2026

    6:20 a.m. May 25, 2020

    - Market Insight Reports

  4. Loading more headlines...
Link to MarketWatch's Slice.